

Quarterly Report October I-December 31, 2021 2021Q4

Virginia Prescription Monitoring Program




Key Findings for the Fourth Quarter (2021Q4)

- 91% of opioid prescriptions are transmitted electronically from prescriber to dispenser.
- Multiple provider episodes, defined as ≥5 prescribers and ≥5 pharmacies in a 6-month period, decreased from 5.5 (2020Q1) to 2.1 per 100,000 this quarter.
- Through this period, 27,659
 prescribers wrote at least one
 prescription for an opioid
 medication dispensed by a Virginialicensed pharmacy.
- Five percent of Virginians, or 404,390 residents, received an opioid prescription. This excludes individuals who received buprenorphine products.



Increasing PMP utilization




- Requests for a patient's prescription history grow exponentially each year
- Rapid rise in utilization of the PMP is primarily the result of expansions in integration within the electronic health record and pharmacy software applications
 - 80% of total requests are through an integrated application



Increasing PMP utilization

Prescription history requests by type, 2020Q1-2021Q4



•Gateway: integrates PMP data within health record clinical workflow •NarxCare (previously AWARxE): web-based application •PMPi: interoperability among states' PMPs



Drug class


Percent change by drug class 2020QI-202IQ4 Opioid* 12%

Benzodiazepine $\sqrt{8\%}$

- Stimulant 12%
- Gabapentinoid $\sqrt{2\%}$

Nonbenzo \downarrow 8% sedative hypnotics


Prescriptions dispensed by drug class, 2020Q1-2021Q4



*All opioids, including drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; opiate partial agonists (e.g., buprenorphine) is excluded



Prescriptions dispensed by drug class, 2020Q1-2021Q4




*All opioids, including drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; opiate partial agonists (e.g., buprenorphine) is excluded

Opioid prescriptions


- 404,390 Virginia residents received an opioid prescription in 2021Q4 from 27,659 unique prescribers
- 13,681,836 opioid prescription days for commonwealth residents during 2021Q4
- Prescription days or days' supply refers to the number of days of medication prescribed

Opioid prescriptions for Virginia residents, 2020Q1-2021Q4



^{*}CDC-defined opioids, excludes: 1) drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; 2) opiate partial agonists (e.g., buprenorphine)






*CDC-defined opioids, excludes: 1) drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; 2) opiate partial agonists (e.g., buprenorphine)



Overlapping prescriptions

Overlapping opioid and opioid-benzodiazepine prescription days, 2020Q1-2021Q4



- Overlapping opioid prescriptions, which increase a patient's MME, and concurrent opioid and benzodiazepine prescribing increases the risk of overdose
- Opioid-benzo days appeared aberrant in 2020QI compared to prior and subsequent quarters
- Opioid-opioid days were comparable in 2021Q4 to 2020Q1 following a year of trending downward


*CDC-defined opioids, excludes: 1) drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; 2) opiate partial agonists (e.g., buprenorphine)



Electronic prescribing for opioids


- Beginning July 1, 2020 any prescription containing an opioid must be transmitted electronically from the prescriber to the dispenser (Code of Virginia § 54.1-3408.02)
- 91% of opioid prescriptions were electronic in 2021Q4

Opioid prescriptions by transmission type, 2020Q1-2021Q4



Patients receiving ≥90 MME/day

Patients receiving ≥90 MME/day, 2021Q4




- Morphine milligram equivalent (MME) allows comparison between the strength of different types of opioids
 - CDC guidelines specify dosages of ≥90/day should be avoided due to risk for fatal overdose
- 6% of opioid prescription recipients had an average dose ≥90 MME/day (2021Q4)

*CDC-defined opioids, excludes: 1) drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; 2) opiate partial agonists (e.g., buprenorphine) Reference: Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: http://dx.doi.org/10.15585/mmwr.rr6501e1



Opioid naïve patients receiving ER/LA opioids

- Extended-release or long acting (ER/LA) opioids put patients at greater risk of respiratory depression and overdose compared to immediate-release (IR)
 - Opioid naïve patients are at particularly high risk of overdose from ER/LA opioids
- Opioid naïve refers to patients who have not taken an opioid medication within the previous 45 days




*CDC-defined opioids, excludes: 1) drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; 2) opiate partial agonists (e.g., buprenorphine)



Multiple provider episodes for opioids

- ≥5 prescribers and ≥5 pharmacies in a 6 month period
- Can be an indicator of doctor shopping and/or inadequate care coordination
- Between 2018Q1 and 2021Q4 dropped from 10.6 to 2.1 per 100,000




^{*}CDC-defined opioids, excludes: 1) drugs not typically used in outpatient settings or otherwise not critical for calculating dosages in MME, such as cough and cold formulas including elixirs, and combination products containing antitussives. decongestants, antihistamines, and expectorants; 2) opiate partial agonists (e.g., buprenorphine)



Opioid prescriptions exceeding 120 MME/day

- Regulations Governing Prescribing of Opioids and Buprenorphine (18VAC85-21-70)
 - Specific requirements of prescribers if exceeding I20 MME/d
- % change, 2020QI-202IQ4
 ≥50 to <90 -12%
 ≥90 to <120 -10%
 ≥120 -22%


Opioid prescriptions by MME/day, 2020Q1-2021Q4






Buprenorphine

- Regulations Governing Prescribing of Opioids and Buprenorphine (18VAC85-21-10, effective March 2017)
 - Limited prescribing buprenorphine without naloxone (mono-product) for opioid use disorder (OUD)
- Buprenorphine is an opiate receptor partial agonist
- Immediate decline in monoproduct prescriptions and continues to decrease marginally (6% in 2021Q4)








Naloxone

- State Health Commissioner's standing order authorizes
 Virginia pharmacies to dispense naloxone without a prescription
- 5% of total dispensations in 2021Q4 were dispensed using the standing order
- Naloxone became reportable to PMP as of July 1, 2018
 - Narcan[®] accounts for 99% of total naloxone dispensations

Naloxone prescriptions dispensed in pharmacies by prescriber, 2020Q1-2021Q4





Technical notes

- Covered substances
 - Schedule II-V medications, naloxone
 - Gabapentin is a Schedule V in Virginia
 - Cannabis oils from in state pharmaceutical processors
- PMP relies on pharmacies and other dispensers to submit accurate, timely information. Dispensers can correct or submit post-dated data at any time; therefore, PMP data is expected to change.
- Quarters referenced are based upon the calendar year.
- Buprenorphine is an opiate receptor partial agonist and is excluded from the opiate receptor full agonist analyses (i.e., "opioid")

- Contact
 - Phone: 804.367.4514
 - Fax: 804.527.4470
 - Email: pmp@dhp.virginia.gov
 - PMP website: https://www.dhp.virginia.gov/dhp_programs/p mp/
 - PMP database: https://virginia.pmpaware.net/login